ScoreWhy is Assembly Biosciences, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -8.71% and Operating profit at 7.10% over the last 5 years
2
The company has declared Positive results for the last 7 consecutive quarters
- NET PROFIT(HY) Higher at USD -19.02 MM
- RAW MATERIAL COST(Y) Fallen by -0.05% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -398.32 %
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 109.65%, its profits have risen by 22.3%
4
High Institutional Holdings at 59.18%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.07% over the previous quarter.
5
Market Beating performance in long term as well as near term
- Along with generating 109.65% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Assembly Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Assembly Biosciences, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Assembly Biosciences, Inc.
139.45%
1.78
64.15%
S&P 500
11.09%
0.60
19.84%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-8.71%
EBIT Growth (5y)
7.10%
EBIT to Interest (avg)
-68.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.34
Sales to Capital Employed (avg)
0.85
Tax Ratio
0.83%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
59.18%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.57
EV to EBIT
-0.75
EV to EBITDA
-0.75
EV to Capital Employed
-0.53
EV to Sales
1.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-147.12%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET PROFIT(HY)
Higher at USD -19.02 MM
RAW MATERIAL COST(Y)
Fallen by -0.05% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -398.32 %
NET SALES(Q)
Highest at USD 9.63 MM
-2What is not working for the Company
ROCE(HY)
Lowest at -147.64%
Here's what is working for Assembly Biosciences, Inc.
Net Profit
Higher at USD -19.02 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
Highest at USD 9.63 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 9.63 MM has Grown at 19.75%
over average net sales of the previous four periods of USD 8.04 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at -398.32 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
